US · USD
VRTX
Vertex Pharmaceuticals Inc
- Day's range
- US$522.74 – US$529.72
- Day's volume
- US$587.3m
- 52-week range
- US$402.90 – US$557.96
Follow VRTX on Fuolio
See how VRTX weighs in your net worth, what it has paid you and how far it is from your target allocation.
Create a free accountVRTX in numbers
- Market cap
- US$132.5bn
- P/E
- 30.08
- P/B
- 6.54
- Dividend yield (12m)
- 0.00%
VRTX trades at 30.08 times its earnings of the last 12 months.
VRTX price history
VRTX risk and return
Monthly closes adjusted for splits and distributions.
| Metric | 12 months | 36 months | 60 months |
|---|---|---|---|
| Return | +33.38% | +50.22% | +187.99% |
| Volatility (annualised) | 24.64% | 26.69% | 25.57% |
| Largest drawdown | -13.98% | -23.25% | -23.25% |
| Positive months | 8/12 | 23/36 | 39/60 |
How much did investing in VRTX return?
US$1,000.00 invested on 01/09/2021 would be worth US$2,879.87 today.
- Value today in VRTX
- US$2,879.87
- Return over the period
- +187.99%
- Return per year
- +23.56%
- In the S&P 500
- US$1,788.52
With dividends reinvested, before taxes and costs, at month-end closes. Past returns do not guarantee future ones.
VRTX fundamentals
Valuation
- P/E30.08
- P/B6.54
- EV/EBITDA26.51
- EV/EBIT27.74
- EV/Revenue10.53
- P/EBIT27.74
- P/S10.53
- P/OCF30.87
- P/FCF34.91
- Earnings yield3.61%
- PEG ratio—
- Earnings per shareUS$17.38
- Book value per shareUS$79.89
Debt
- Net debt—
- Net debt/EBITDA—
- Net debt/Equity—
- Debt/Equity—
- Current ratio3.19
- Quick ratio2.74
- Cash ratio1.99
Efficiency
- Gross margin86.00%
- EBITDA margin39.72%
- Operating margin37.95%
- Net margin35.00%
- Asset turnover0.46
Profitability
- ROE21.76%
- ROA16.06%
- ROIC19.70%
- Payout0.00%
Growth
- Revenue CAGR (5 years)13.50%
- Earnings CAGR (5 years)17.21%
- Revenue growth (year)—
- Earnings growth (year)—
- Revenue growth (quarter)—
- Earnings growth (quarter)—
What is VRTX's fair price?
Two classic value formulas, with today's numbers. The current price is US$522.81.
- Graham's fair price
- US$176.75
- 66.19% below the price
√(22.50 × US$17.38 × US$79.89)
Benjamin Graham paid no more than a P/E of 15 and a P/B of 1.5. Their product, 22.5, times earnings (EPS) and book value per share gives the fair price.
- Bazin's ceiling price
- —
- Does not apply to VRTX: it paid no distributions in the last five years.
Décio Bazin only bought shares yielding at least 6% a year in distributions. The ceiling price is the average dividend per share of recent years divided by 6%.
Graham ignores growth and debt; Bazin assumes past distributions will repeat. They are reference points for comparison, not a buy recommendation.
VRTX indicators by year
Multiples at each year's closing price; margins and returns from that year's accounts.
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| P/E | 29.13 | -193.07 | 29.04 | 22.35 | 23.87 | 22.66 | 48.24 | 20.20 |
| P/B | 6.17 | 6.30 | 5.98 | 5.34 | 5.54 | 7.07 | 9.33 | 9.55 |
| EV/EBITDA | 26.28 | — | 26.19 | 16.66 | 19.23 | 20.72 | 43.52 | 59.87 |
| Earnings per share | US$15.56 | -US$2.09 | US$14.01 | US$12.92 | US$9.20 | US$10.43 | US$4.54 | US$8.20 |
| Book value per share | US$73.48 | US$63.90 | US$68.06 | US$54.12 | US$39.67 | US$33.42 | US$23.47 | US$17.35 |
| ROE | 21.18% | -3.26% | 20.59% | 23.88% | 23.19% | 31.22% | 19.34% | 47.28% |
| ROIC | 19.04% | 0.00% | 18.01% | 24.30% | 23.63% | 28.61% | 16.60% | 14.32% |
| Gross margin | 86.24% | 86.11% | 87.21% | 87.90% | 88.06% | 88.14% | 86.84% | 86.56% |
| EBITDA margin | 36.52% | -0.23% | 40.66% | 49.89% | 38.39% | 47.79% | 31.33% | 23.22% |
| Net margin | 32.94% | -4.86% | 36.68% | 37.20% | 30.92% | 43.70% | 28.27% | 68.80% |
VRTX financial statements
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net revenue | US$12bn | US$11bn | US$9.9bn | US$8.9bn | US$7.6bn | US$6.2bn |
| Cost of sales | -US$1.7bn | -US$1.5bn | -US$1.3bn | -US$1.1bn | -US$904.2m | -US$736.3m |
| Gross profit | US$10.4bn | US$9.5bn | US$8.6bn | US$7.9bn | US$6.7bn | US$5.5bn |
| EBITDA | US$4.4bn | -US$25.7m | US$4bn | US$4.5bn | US$2.9bn | US$3bn |
| EBIT | US$4.2bn | -US$232.9m | US$3.8bn | US$4.3bn | US$2.8bn | US$2.9bn |
| Net finance result | — | — | — | — | — | — |
| Profit before tax | US$4.6bn | US$248.5m | US$4.4bn | US$4.2bn | US$2.7bn | US$3.1bn |
| Income tax | -US$690m | -US$784.1m | -US$760.2m | -US$910.4m | -US$388.3m | -US$405.2m |
| Net income | US$4bn | -US$535.6m | US$3.6bn | US$3.3bn | US$2.3bn | US$2.7bn |
Figures the company filed with the CVM. Debt excludes leases; each quarter is that quarter alone.
Does VRTX pay dividends?
VRTX has no distributions on record.
About Vertex Pharmaceuticals
- Sector
- Manufacturing
Questions about VRTX
How much is VRTX today?
VRTX is at US$522.81 (-0.74% on the day), last traded on 30/09/2026.
What are the P/E and P/B of VRTX?
VRTX trades at a P/E of 30.08 and a P/B of 6.54.
How much did VRTX return in 12 months?
VRTX returned 33.38% in 12 months, with annualised volatility of 24.64% and a largest drawdown of -13.98%.